ScholarIQanswers from OpenAlex & ORCID
Hyun Cheol Chung
ResearcherPublications, citations & collaboration network
Hyun Cheol Chung is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Hyun Cheol Chung have?
ScholarIQindexed works
Hyun Cheol Chung has 1,666 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Hyun Cheol Chung have?
ScholarIQcitation count
Hyun Cheol Chung has 56,609 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Hyun Cheol Chung?
ScholarIQh-index
Hyun Cheol Chung has an h-index of 88 in OpenAlex.
What is the i10-index of Hyun Cheol Chung?
ScholarIQi10-index
Hyun Cheol Chung has an i10-index of 411 in OpenAlex.
What is the ORCID of Hyun Cheol Chung?
ScholarIQorcid
The ORCID for Hyun Cheol Chung is on the source record.
What is the OpenAlex record for Hyun Cheol Chung?
ScholarIQopenalex
The OpenAlex for Hyun Cheol Chung is on the source record.
What are the most-cited papers on Hyun Cheol Chung?
ScholarIQmost cited works
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph P. Eder, Barbara Burtness, Se‐Hoon Lee, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Jared Weiss, Ravit Geva, Chia‐Chi Lin, Hyun Cheol Chung, Amy Meister, Marisa Dolled‐Filhart, Kumudu Pathiraja, Jonathan D. Cheng, Tanguy Y. Seiwert
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo, Chia-Jui Yen, Ronnie T. P. Poon, Davide Pastorelli, Jean-Frédéric Blanc, Hyun Cheol Chung, Ari David Baron, Túlio Pfiffer, Takuji Okusaka, Kateřina Kubáčková, Jörg Trojan, Javier Sastre, Ian Chau, Shao-Chun Chang, Paolo Abada, Ling Yang, Jonathan D. Schwartz, Masatoshi Kudo
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yañez, Ning Li, Sara Lonardi, О. P. Коlesnik, Olga Barajas, Yuxian Bai, Lin Shen, Yong Tang, Lucjan Wyrwicz, Jianming Xu, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Lie Li, Sukrut Shah, Pooja Bhagia, Hyun Cheol Chung
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
Taroh Satoh, Rui‐Hua Xu, Hyun Cheol Chung, Guoping Sun, Toshihiko Doi, Jianming Xu, Akihito Tsuji, Yasushi Omuro, Jin Li, Jinwan Wang, Hiroto Miwa, Shukui Qin, Ik‐Joo Chung, Kun‐Huei Yeh, Jifeng Feng, Akihira Mukaiyama, Mikiro Kobayashi, Atsushi Ohtsu, Yung‐Jue Bang
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu, Kazushi Numata, Stacey Stein, Wendy Verret, Stephen P. Hack, Jessica Spahn, Bo Liu, Heba Abdullah, Yulei Wang, Aiwu Ruth He, Kyung-Hun Lee, Y-J. Bang, Johanna C. Bendell, Yee Chao, J-S Chen, Hyun Cheol Chung, S. Lindsey Davis, Atul Dev, Edward Gane, Ben George, Aiwu Ruth He, Howard S. Höchster, C-H Hsu, Masafumi Ikeda, Jes Chauviere Lee, M. Lee, Amit Mahipal, Gulam A. Manji, Manabu Morimoto, Kazushi Numata, Michael J. Pishvaian, Shukui Qin, David P. Ryan, B-Y Ryoo, Naoki Sasahira, Stacey Stein, John H. Strickler, N. C. Tebbutt